Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 01, 2018 16:29 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
August 01, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release Second Quarter 2018 Financial Results and Host Conference Call and Webcast on August 6

EMERYVILLE, Calif., Aug. 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
July 12, 2018 07:00 ET | Source: Zogenix, Inc.

Zogenix Announces Positive Top-line Results from Second Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome

Primary Endpoint Achieved - Statistically Significant Convulsive Seizure Reduction for ZX008 versus Placebo for Adjunctive Treatment of Seizures ZX008 Also Demonstrated Statistical Significance in...
July 02, 2018 16:32 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
July 02, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix Welcomes New Global Chief Commercial Officer

Ashish Sagrolikar Brings Over 25 Years of Global Pharmaceutical Sales, Marketing and Operations Experience to Zogenix EMERYVILLE, Calif., July 02, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc....
June 01, 2018 16:24 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., June 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
May 14, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Participate in the Bank of America Merrill Lynch 2018 Healthcare Conference

EMERYVILLE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
May 09, 2018 16:01 ET | Source: Zogenix, Inc.

Zogenix Provides Corporate Update and Reports First Quarter Financial Results

Following receipt of Breakthrough Therapy Designation, conducted successful Type B meeting with FDA confirming adequacy of Phase 3 program for ZX008 NDA in Dravet syndromeStudy 1504 fully enrolled...
May 04, 2018 08:00 ET | Source: Zogenix, Inc.

Zogenix to Release First Quarter 2018 Financial Results and Host Conference Call and Webcast on May 9

EMERYVILLE, Calif., May 04, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...
May 01, 2018 17:00 ET | Source: Zogenix, Inc.

Zogenix Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

EMERYVILLE, Calif., May 01, 2018 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders,...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right